Development and Validation of a Sensitive UHPLC-MS/MS Method for Teduglutide Analysis in Human Plasma on LCMS-8060RX

Significance of the Topic

The accurate and sensitive quantification of teduglutide, a synthetic GLP-2 analog used in short bowel syndrome therapy, is critical for bioequivalence assessments and therapeutic monitoring. Reliable plasma analysis ensures proper dose optimization, supports generic formulation development, and underpins regulatory compliance in pharmacokinetic and clinical studies.

Study Objectives and Overview

This study aimed to develop and partially validate a robust ultra-high performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS) method for precise measurement of teduglutide in human plasma. Key goals included achieving a wide dynamic range, high recovery, minimal matrix effects, and full compliance with ICH M10 guidelines.

Methodology and Instrumentation

Sample Preparation:

• Human K₂EDTA plasma was spiked with calibration standards (0.5–100 ng/mL) and QC samples (0.5–50 ng/mL).
• Protein precipitation with methanol, centrifugation, followed by SPE on mixed-mode anion exchange cartridges.
• Wash steps with ammonia/methanol:water and acidified acetonitrile, elution with formic acid in acetonitrile:water.

Chromatography and Mass Spectrometry:

• Shimadzu Nexera X2 UHPLC with Shim-pack Scepter C18 column (1.9 µm, 100 × 3.0 mm).
• Mobile phase A: 0.1% formic acid in water; B: 0.1% formic acid in acetonitrile; gradient elution at 0.5 mL/min and 50 °C.
• Shimadzu LCMS-8060RX ESI-MS/MS in MRM mode, optimized gas flows and temperatures.

Main Results and Discussion

Selectivity and Linearity:
The method demonstrated minimal endogenous interference (<5.7%) across six plasma lots. An eight-point calibration curve (0.5–100 ng/mL) with 1/x² weighting achieved excellent linearity (r² = 0.9930).

Precision and Accuracy:
Intra- and inter-day precision (CV) remained below 10.7%, while accuracy ranged from 100.2% to 105.4% across LLOQ, LQC, MQC, and HQC levels.

Recovery and Matrix Effect:
Global recovery averaged 97.83% (RSD 2.43%). Matrix factor values at LQC and HQC were 0.96 and 0.98, indicating negligible ion suppression or enhancement.

Carry-Over:
No detectable carry-over was observed following the highest calibration standard injection.

Benefits and Practical Applications

The validated UHPLC-MS/MS method offers rapid throughput, high sensitivity (LLOQ 0.5 ng/mL), and reliable quantification, making it suitable for pharmacokinetic profiling, bioequivalence trials, and therapeutic drug monitoring of teduglutide. The streamlined sample preparation and robust chromatographic performance support high sample workloads in research and quality control laboratories.

Future Trends and Potential Applications

Advancements in microflow UHPLC and high-resolution MS may further lower detection limits and reduce solvent consumption. Integration with automated sample preparation platforms and AI-driven data analysis could enhance throughput and data quality. Expanding the method to quantify related peptide analogs will support broader clinical applications and novel GLP-2 analog development.

Conclusion

A sensitive and reliable UHPLC-MS/MS assay for teduglutide in human plasma was successfully developed and partially validated according to regulatory guidelines. The method demonstrates excellent linearity, precision, accuracy, and recovery with negligible matrix effects and carry-over, positioning it as a valuable tool for bioanalytical studies.

Reference

• ICH M10 Bioanalytical Method Validation and Study Sample Analysis. Step 4, May 2022.